Physician profile
David M Page
NPI 1598768848
$13,723.74
in general payments reported to CMS, 2019-2025
46 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $1,838 · 2021: $2,919 · 2022: $1,547 · 2023: $1,969 · 2024: $2,294 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,382.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,843.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,422.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,154.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $865.25 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $843.47 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $694.00 | 2021-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $504.83 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $487.95 | 2019-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $469.01 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.38 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $321.15 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Axsome Therapeutics, INC. | $320.78 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $279.06 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $278.30 | 2024-2025 | Voquezna |
| Allergan, INC. | $272.12 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.